Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.45 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.45 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9567 | 0.78 | CA2 (0.50) | CA2CA12CA1CA9CHKA | |
| SCHEMBL2910471 | 0.78 | CA2 (0.50) | CA2CA12CA1CA9CHKA | |
| SCHEMBL424151 | 0.78 | CA2 (0.50) | CA2CA12CA1CA9CHKA | |
| SCHEMBL13747729 | 0.76 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL8343658 | 0.76 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL3654737 | 0.76 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL5912624 | 0.76 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL5423307 | 0.76 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL894533 | 0.76 | CHRNB2 (0.50) | CA2CA12CA1CA9CHKA | |
| SCHEMBL3236363 | 0.76 | ALDH1A1 (0.52) | CA2CA12CA1CA9CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | claimed |
| WO-2021094974-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | claimed |
| EP-3821947-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | claimed |
| EP-4743446-A1 | NITRO-CONTAINING COMPOUNDS THAT KILL MYCOBACTERIA | Board of Trustees of Michigan State University (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| WO-2025215110-A1 | NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2025-10-16 | — | — | WO | disclosed |
| EP-3526220-B1 | COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE | US HEALTH (US) | 2025-06-11 | — | — | EP | disclosed |
| US-12275727-B2 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| WO-2025015066-A1 | NITRO-CONTAINING COMPOUNDS THAT KILL MYCOBACTERIA | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2025-01-16 | — | — | WO | disclosed |
| EP-4488275-A1 | COMPOUND CONTAINING FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Yingli Pharmaceutical Co., Ltd (CN) | 2025-01-08 | — | — | EP | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-7176202-B2 | Benzamide inhibitors of the P2X7 receptor | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20070021435-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20060084660-A1 | Psychological disorders; analgesics; Parkinson's disease; antiepileptic agents; irritable bowel disorders; antiarrhythmia agents | NEUROMED TECHNOLOGIES INC. | 2006-04-20 | — | — | US | disclosed |
| US-20040259866-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-12-23 | — | — | US | disclosed |
| US-20040209872-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275727-B2 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | PARG, CYP3A5, CYP11B1 | CA2 4434/4885CA12 4152/4885CA1 4642/4885 |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | CA2 1829/4885CA12 2828/4885CA1 2610/4885 |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | CA2 2701/4885CA12 2406/4885CA1 3203/4885 |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | NCOR1, HAVCR2, NR3C1 | CA2 1795/4885CA12 975/4885CA1 2888/4885 |
| US-20040209872-A1 | Calcium channel blockers comprising two benzhydril moieties | CACNA1C, CACNA1F, CACNA1D | CA2 75/4885CA12 1161/4885CA1 301/4885 |
| US-20060084660-A1 | Psychological disorders; analgesics; Parkinson's disease; antiepileptic agents; irritable bowel disorders; antiarrhythmia agents | CACNA1D, CACNA1E, CACNA1B | CA2 311/4885CA12 2951/4885CA1 1378/4885 |
| US-20040259866-A1 | Calcium channel blockers comprising two benzhydril moieties | CACNA1C, CACNA1F, CACNA1D | CA2 75/4885CA12 1161/4885CA1 301/4885 |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | TRPM7, TRPM2, TRPM5 | CA2 740/4885CA12 3610/4885CA1 2132/4885 |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | CA2 2749/4885CA12 1676/4885CA1 4374/4885 |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | KIT, PRKCH, PRKCE | CA2 764/4885CA12 1969/4885CA1 2011/4885 |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | CDKL2, CDK2, CDKL1 | CA2 2941/4885CA12 4523/4885CA1 4042/4885 |
| US-20070021435-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | FLT3, KIT, TK1 | CA2 3573/4885CA12 4632/4885CA1 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.